Drug Profile
AP 101
Alternative Names: AP 101 - AL-S Pharma; AP-101; NI 005Latest Information Update: 04 Dec 2023
Price :
$50
*
At a glance
- Originator AL-S Pharma
- Class Monoclonal antibodies
- Mechanism of Action Superoxide dismutase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis
Most Recent Events
- 23 Nov 2023 Université de Sherbrooke, Eli Lilly and Company and AL-S Pharma AG initiates a phase I PK trial (In volunteers) in Canada (NCT05974579)
- 31 Aug 2021 Phase-II clinical trials in Amyotrophic lateral sclerosis in Canada (IV) (NCT05039099)
- 28 Jul 2021 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in Switzerland (IV, Infusion)